Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri 63110, USA.
Urology. 2010 Sep;76(3):593-9. doi: 10.1016/j.urology.2010.01.032. Epub 2010 Apr 8.
OBJECTIVES: To compare the 1973 and 2004 World Health Organization (WHO) systems for the interval to tumor recurrence (TR), tumor progression (TP), and overall survival (OS) using either the superficial/muscle invasive or strict TMN pathologic staging in patients with urothelial carcinoma with ≥10 years of follow-up. METHODS: A total of 269 tumors from an institutional review board-approved bladder tumor registry were graded using the 1973 and 2004 WHO systems. Kaplan-Meier plots, the log-rank test, the chi-square test, and the Cox proportional hazard model were used to relate the clinical and histologic variables. RESULTS: The Cox model analyses, which were multivariate and included tumor stage (coded as pT1 or less versus pT2 or greater) as a significant covariate to grade, were performed and in all tumor stages were significant. The 2004 WHO grading system was more closely associated with TR (P = .025) and TP (P = .012) than was the 1973 WHO grading system (P = .47, and P = .046, respectively). OS was similar and significant for both. The OS plots for the 1973 WHO system showed a significant overlap between Stage pT1 or less, grade 2 and 3 tumors. For those with high-grade Stage pTa and high-grade Stage pT1 disease, TR and TP were similar; however, OS was significantly longer (P = .05, log-rank test) for those with Stage pTa. The OS was similar for those with high-grade Stage pT1 disease and those with Stage pT2 or greater (P = .069, log-rank test). For those with pTa, the 2004 system predicted TR and TP, but the 1973 system only predicted TP. Neither predicted OS. CONCLUSIONS: The results of our analysis have shown that the 2004 WHO system is superior to the 1973 system for predicting clinical outcomes in patients with urothelial carcinoma, independent of pathologic stage. Its primary usefulness is in those with Stage pTa.
目的:比较采用 1973 年和 2004 年世卫组织(WHO)系统对浸润性膀胱癌患者肿瘤复发(TR)、肿瘤进展(TP)和总生存(OS)的间隔时间,这些患者的随访时间均超过 10 年,且采用了浅表/肌层浸润或严格的 TMN 病理分期。
方法:使用 1973 年和 2004 年 WHO 系统对机构审查委员会批准的膀胱肿瘤登记处的 269 例肿瘤进行分级。采用 Kaplan-Meier 图、对数秩检验、卡方检验和 Cox 比例风险模型分析与临床和组织学变量的关系。
结果:Cox 模型分析为多变量分析,包括肿瘤分期(编码为 pT1 或更低与 pT2 或更高)作为分级的显著协变量,并在所有肿瘤分期中均有显著意义。2004 年 WHO 分级系统与 TR(P =.025)和 TP(P =.012)的相关性比 1973 年 WHO 分级系统更密切(P =.47 和 P =.046)。OS 对两者都有相似的重要意义。1973 年 WHO 系统的 OS 图显示,pT1 或更低和 2 级和 3 级肿瘤的分期 pT1 或更低之间存在显著重叠。对于高级别 pTa 和高级别 pT1 疾病,TR 和 TP 相似;然而,pTa 期的 OS 明显更长(P =.05,对数秩检验)。高级别 pT1 疾病和 pT2 或更高的 OS 相似(P =.069,对数秩检验)。对于 pTa 患者,2004 年系统预测 TR 和 TP,但 1973 年系统仅预测 TP。两者均未预测 OS。
结论:我们的分析结果表明,2004 年 WHO 系统在预测浸润性膀胱癌患者的临床结果方面优于 1973 年 WHO 系统,与病理分期无关。其主要用途是在 pTa 期患者中。
J Cancer Res Clin Oncol. 2019-6-21
World J Urol. 2018-9-14
Diagn Interv Radiol. 2018-9